More common than cervical cancer, cervical intraepithelial neoplasia (CIN) represents a precursor lesion of cervical carcinoma, being associated with HPV infection. Due to the bidirectional relationship between HPV and estrogen and progesterone in pregnancy, most of the published data claim that precancerous lesions remain stable or even regress during pregnancy, although several studies have indicated the tendency of HSILs to persist. It is considered that pregnancy-related cervical precancerous lesions undergo a postpartum regression, due to stimulatory effects of the immune microenvironment. Due to the rarity of publications on this subject, we aimed to offer a concise overview of and new insights into the current knowledge regarding the pathogenesis, diagnosis, and evolution of pregnancy-associated precancerous lesions, as well as their impact upon gestation and fertility.

Neonatal infections remain a leading cause of morbidity and mortality worldwide, particularly among preterm and low-birth-weight infants and in low- and middle-income countries. This burden has intensified with the global increase in multidrug-resistant (MDR) bacteria, especially in neonatal intensive care units, where prolonged hospitalization, invasive interventions, and exposure to broad-spectrum antibiotics promote colonization, transmission, and invasive infection. In this narrative review, we explore the epidemiology and microbiological characteristics of MDR bacterial infections in newborns, alongside their associated risk factors, diagnostic challenges, treatment outcomes, and prevention strategies. Across different settings, Gram-negative pathogens, particularly Klebsiella pneumoniae, Escherichia coli, and Acinetobacter baumannii, account for a substantial proportion of severe neonatal infections, whereas methicillin-resistant Staphylococcus aureus remains important in selected units. The risk of MDR infection is driven by a complex interplay of factors, ranging from maternal and perinatal exposures to the inherent immunological vulnerability of newborns, hospital-based transmission, antibiotic selection pressure, and structural deficiencies in healthcare infrastructure. Diagnosis remains challenging because clinical presentations are nonspecific and culture-based methods are constrained by low blood volumes, prior antimicrobial exposure, and delayed turnaround times. Treatment is increasingly complicated due to resistance to standard empirical regimens, substantial regional variation in susceptibility profiles, and limited neonatal pharmacokinetic and safety data for reserve agents. Current evidence mainly supports surveillance-informed empirical therapy, susceptibility-guided treatment adjustment, antimicrobial stewardship, and strict infection prevention measures. Future progress will require neonatal-specific clinical trials, harmonized surveillance systems, stronger molecular epidemiology, and more equitable access to microbiological diagnostics and effective treatment.

(1) Background: Candida-positive cultures in pregnancy and the postpartum period are frequently identified in obstetric and gynecological practice. This study evaluated species distribution and associated maternal and obstetric variables in amniotic fluid, vaginal discharge, and lochial cultures. (2) Methods: A retrospective, single-center, cross-sectional comparative study was conducted at the “Cuza Vodă” Clinical Hospital of Obstetrics and Gynecology, Iași, including Candida-positive samples collected in 2024 (242 amniotic fluid, 2020 vaginal discharge, and 827 lochial isolates). Fungal identification was performed using Sabouraud and chromogenic media, with species-level identification in most cases and classification as Candida spp. when differentiation was not possible. (3) Results: Candida albicans predominated across all compartments (69.8%, 55.3%, and 66.9%, respectively), followed by non-albicans species, mainly Pichia kudriavzevii. Vaginal discharge cultures, obtained from both pregnant and non-pregnant women and analyzed after stratification by pregnancy status, showed multiple significant associations with maternal and obstetric variables; apparent associations with fetal variables were largely attributable to the inclusion of non-pregnant women and were not retained within the pregnant stratum. Amniotic fluid and lochial cultures demonstrated limited associations. Older maternal age was the only consistent independent correlate of non-albicans Candida isolation, whereas the remaining associated variables were compartment-specific. Multivariable models identified compartment-specific correlates of non-albicans Candida isolation but showed limited discriminatory performance, with low sensitivity in most strata. (4) Conclusions: Candida species distribution is compartment-dependent, with greater clinical heterogeneity in vaginal discharge and more limited patterns in amniotic fluid and lochia. These culture-positive findings support species-level identification for microbiological surveillance and provide perinatal microbiological context for future integrated maternal–neonatal studies; because antifungal susceptibility and neonatal outcomes were not assessed, no therapeutic or neonatal inferences can be drawn.

Background and Objectives: Topical diclofenac is recommended over oral non-steroidal anti-inflammatory drugs (NSAIDs) for osteoarthritis, particularly in older adults and those with comorbidities, on the assumption that low systemic absorption limits renal effects. Whether this presumed safety extends to patients already at increased risk of kidney injury has not been systematically evaluated. This review assessed the evidence on renal outcomes of topical diclofenac in adults. Materials and Methods: We conducted a systematic review (PROSPERO CRD420261393454) of studies reporting renal outcomes after topical diclofenac exposure. PubMed, Embase, Web of Science, and Scopus were searched from inception to 19 April 2026. Studies were stratified a priori into increased-renal-risk and general populations and synthesised separately, without pooling. Risk of bias was assessed with RoB 2, ROBINS-I, and JBI tools, certainty with GRADE, and synthesis followed the SWiM framework. Results: Eighteen studies, contributing data from more than 500,000 participants, were included; 14 underwent primary risk-of-bias appraisal (three at low, three at serious or high risk). In general populations, topical diclofenac produced little to no change in serum creatinine or creatinine clearance and smaller renal effects than oral diclofenac, providing high-certainty evidence of a favourable profile. In increased-renal-risk populations, one adjusted cohort reported higher acute kidney injury (AKI) risk among topical NSAID users, although exposure was predominantly to non-diclofenac agents; within the same cohort, topical NSAIDs carried lower risk than systemic NSAIDs. No study evaluated early renal injury biomarkers; certainty was moderate owing to indirectness. Conclusions: Relative to oral diclofenac, topical diclofenac shows a favourable renal safety profile, with high-certainty evidence in general populations. In adults at increased renal risk, moderate-certainty evidence derived from predominantly non-diclofenac exposure over short observation windows cannot exclude a modest excess of any-stage AKI; renal risk therefore appears reduced rather than absent. Diclofenac-specific studies in chronic kidney disease using sensitive biomarkers and longer follow-up are needed.

Neonatal sepsis remains a leading cause of morbidity and mortality in the first month of life, yet its presentation is nonspecific, and its microbiological confirmation is uniquely difficult. Low-circulating bacterial loads, small obtainable blood volumes, frequent intrapartum antibiotic exposure, and the ambiguity of skin-commensal isolates erode the sensitivity and specificity of blood culture, the long-standing reference standard, so that most evaluated infants are treated empirically despite sterile cultures. This review synthesizes current evidence on the integrated microbiological evaluation of the newborn: the host- and specimen-related diagnostic challenge; the etiologic spectrum and its antimicrobial-resistance burden; conventional culture; rapid and molecular methods, including mass spectrometry and syndromic and broad-range PCR; metagenomic and cell-free-DNA sequencing; host-response biomarkers; and antimicrobial-susceptibility determination. The evidence indicates that newer methods accelerate or supplement culture but do not yet replace it, each addressing one limitation while introducing caveats of its own. Notably, much of the evidence for direct-from-blood molecular testing, microbial cell-free DNA, and metagenomic sequencing is extrapolated from adults, whereas neonatal data are stronger for several biomarkers. The greatest benefit arises from integrating complementary modalities within diagnostic- and antimicrobial-stewardship frameworks. Neonatal-specific validation, standardized thresholds, and outcome-driven trials remain the principal priorities.

Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently endorsed in dentistry practice for their effectiveness in analgesia and anti-inflammation, especially in managing odontogenic pain. The growing data connecting NSAID usage to adverse renal effects, such as acute kidney injury, exacerbation of chronic kidney disease, and electrolyte disturbances, prompts significant concerns, particularly regarding indiscriminate use or administration in at-risk populations. This narrative review examines the pathophysiological mechanisms underlying NSAIDs-induced nephrotoxicity, evaluates clinical evidence regarding renal outcomes associated with NSAIDs use, and highlights the risk factors that exacerbate renal impairment. It highlights the importance of enhanced awareness, patient screening, and interdisciplinary communication to mitigate nephrotoxic risks by connecting pharmacological insights with dental prescribing practices. The findings advocate for prudent NSAIDs application in dental care and recommend updating guidelines to address renal safety considerations.